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1. Introduction1
Dysfunctional uterine bleeding is caused by abnormal 
uterine bleeding caused by the hypothalamic pituitary 
ovarian dysfunction. It is a common reproductive endo-
crine disease, non-organic pathologic mutation, complex 
pathogenesis, with 10% incidence rate. Previously patients 
were treated by artificial synthesis of progesterone treat-
ment method which resulted invalid or repeatedly symp-
toms, and ultimately choose the treatment of hysterecto-
my. Foreign research data show that levonorgestrel (trade 
name: Mirena) treatment of perimenopausal dysfunc-
tional uterine bleeding effect is remarkable, therefore, in 
this study selected 126 outpatient of dysfunctional uterine 
bleeding which hospitalize from December 2010 to De-
cember 2012 at department of gynaecology was placed on 
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levonorgestrel treatment to analyze and evaluate the safety 
and clinical efficacy.
2. Materials and methods
2.1. General information
Select 126 cases of dysfunctional uterine bleeding pa-
tients treated in our hospital from December 2010 to 
December 2012. The patients were treated as the research 
object, and the clinical data of the patients were analyzed 
with the approval of the ethics committee and informed 
consent of the patients. Subjects aged 28−54 years old, 
with average (45.3 ± 7.4) years old, and bleeding time was 
21 d to 4 months, which average bleeding time was (65 
± 1.6) d. 126 patients was excluded from levonorgestrel 
allergic, cervical atypical hyperplasia or cervical cancer, 
serious heart, liver and kidney disease. There was no sta-
tistical difference in the clinical data of all patients (p > 
0.05).
2.2. Treatment method
Ultrasonography were used to understand condition such 
as uterine size, sub endometrial thickness, endometrial 
blood supply. Besides, according to the treatment of the 
clinical manifestations, diagnostic curettage or hysterosco-
py, levonorgestrel was placed on 5−7 days of menses. The 
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endometrial thickness, PBAC score, and hemoglobin level 
were detected before and 3, 6, 12 months after placement. 
Observation was did on patients with adverse reactions af-
ter levonorgestrel [1].
2.3. Curative effect judgment
According to the “Practice of Clinical Medicine Develop-
ment” the efficacy criteria included: (1) Excellent: Absent 
of adverse reaction after levonorgestrel treatment and ab-
sent of dysfunctional uterine bleeding clinical symptoms; 
(2) Effective: Absent of adverse reaction after levonorg-
estrel treatment and clinical symptoms of dysfunctional 
uterine bleeding disminish; (3) Invalid: Slightly adverse 
effect occur after levonorgestrel treatment and improve 
or worsen of dysfunctional uterine hemorrhage clinical 
symptoms.
Total effective = (1) / [(1) + (2) + (3)] * 100%.
2.4. Statistical methods
All the data in this study were processed by SPSS 17.0 sta-
tistical software. The data were measured by means of ( x ± 
s) and calculative data analyzed by t test, and the data were 
determined by (x2). p < 0.05 means the statistical difference 
between two groups of data compared.
3. Results
3.1. Menstrual quantity changes
Changes of menstrual discharge: follow-up after 3 months 
use of levonorgestrel, all menstrual volume significantly 
reduced, there are 30 cases (23.8%) showed irregular vagi-
nal bleeding and during 6 months follow-up, 18 cases 
(14.3%) of irregular bleeding which was significantly re-
duced, 5 cases of amenorrhea; amenorrhea after 12 months 
increased to 9 cases (14.3%), the specific amount of men-
strual Pictorial Blood Loss Assessment (PBAC) score see 
Table 1. If amenorrhea patients should stop PBAC score 
immediately [2].
Table 1. The amount of PBAC score before and after place-
ment.
Follow up time Cases (n) PBAC score
Before placing 126 130.5 ± 45.6
In 3 months 126 58.6 ± 17.8
6 months 121 42.3 ± 10.5
12 months 117 26.4 ± 6.5
3.2. Hemoglobin level and endometrial thickness
Hemoglobin levels and endometrial thickness changes: 
Administration of levonorgestrel after 6 months, all pa-
tients hemoglobin concentration increased and endome-
trial thickness decreased, while after 12 months, hemoglo-
bin levels returned to normal; the results of endometrial 
thickness and hemoglobin levels before and after treatment 
are shown in Table 2.
Table 2. Hemoglobin level and endometrial thickness before 
and after placement.
Follow up time Cases (n)
Hemoglobin 
level (g/L)
Endometrial 
thickness (mm)
Before placing 126 85 ± 13 12.5 ± 5.2
In 3 months 126 97 ± 12 8.3 ± 2.8
6 months 121 116 ± 10 6.0 ± 2.2
12 months 117 116 ± 11 5.2 ± 1.0
Note: Hb level p = 0.005 < 0.05, endometrial thickness p = 0.01 < 
0.05, the difference was statistically significant.
3.3. Adverse reactions
Adverse reactions: patients suffer with interval headache 
1 cases, the proportion was 0.79%, 2 cases of nausea, the 
proportion was 1.59%, 12 cases of mild headache, the pro-
portion was 9.52%, 20 cases of slight nausea, the propor-
tion was 15.83%. Compared with the general and does not 
affect the use of medicine and efficacy. Specific results are 
shown in Table 3.
Table 3. The total effective rate of treatment was [n (%)].
Group Cases Headache Nausea Mild 
headache
Mild 
nausea
Observation 
group
126 1 (0.79) 2 (1.59) 12 (9.52) 20 (15.87)
3.4. Treatment efficiency analysis
The excellent treatment was 89, the effective rate was 
70.63%, the effective was 31, the effective rate was 24.61%, 
6 cases were invalid, the ineffective rate was 4.76%, and the 
total effective rate was 95.24%. Specific results are shown 
in Table 4.
Table 4. The total effective rate of treatment was [n (%)].
Group Cases Excellence Effective Invalid Total 
effective
Observation 
group
126 89 (70.63) 31 (24.61) 6 (3.33)
120 
(95.24)
4. Discussion
Dysfunctional uterine bleeding is caused by the hypotha-
lamic-pituitary-ovarian dysfunction. It is a common endo-
crine reproductive disease, but there is no organic disease 
in the whole body included internal and external genital 
organs. It has been reported that the incidence of func-
tional bleeding in patients with uterine bleeding accounted 
for 20−40%, which became a serious threat to the majority 
of women’s physical and mental health [3−5]. Traditional 
progesterone treatment was long which took 3−6 months, 
partial patient experience invalid treatment or recurrence 
after discontinuation of treatment, and even persistent or 
recurring abnormal uterine bleeding and become obsti-
nate dysfunctional uterine bleeding. Hysterectomy had the 
curative effect in the treatment of obstinate dysfunctional 
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uterine bleeding, but it cause permeant effect in patients 
with ovarian function and early menopausal symptoms. 
Most patients’ psychological unacceptable, especially 
young women. Therefore, it is necessary to seek a safe, 
simple and effective alternative treatment method.
Levonorgestrel is 1 times more potent than norgestrel 
which commonly used in clinical to treat irregular men-
struation cycle, endometrial endometriosis, dysfunctional 
uterine bleeding and used as an emergency contracep-
tive. In recent years clinicians begin to apply it for the 
dysfunctional uterine bleeding treatment, as the mecha-
nism of action was targeting hypothalamus and pituitary, 
which make the peak of follicle-stimulating hormone and 
luteinizing hormone reduced, inhibit ovulation, effects on 
the endometrium become low column shape changes in a 
state of atrophy, and to achieve hemostasis purposes [6]. 
Mechanism of levonorgestrel and oral progestin for peri-
menopausal dysfunctional uterine bleeding treatment are 
basically the same, but the former produce local action in 
the uterus. Levonorgestrel rapidly absorbed by capillary 
network of endometrial basal layer into the blood circula-
tion, concentration of local endometrial 1000 times more 
higher than that in peripheral blood circulation, hence pos-
sess an advantages in occupying the local progesterone re-
ceptors, and further inhibit the synthesis of estrogen recep-
tor, therefore administration of levonorgestrel reduce the 
menstrual discharge, and even amenorrhea. And the use of 
levonorgestrel after 6 months all patients’ hemoglobin con-
centration increased, endometrial thickness decreased, after 
12 months of hemoglobin levels were restored to normal.
68.0% of the patients on levonorgestrel shown rapid he-
mostasis within 6 h, 32.0% of patients’ hemostasis within 
24‒48 hours. After 6 months follow-up, irregular bleed-
ing was significantly reduced, which dropped to 18 cases 
(14.3%), and 108 patients returned to normal, the effective 
rate was 85.7%. After 3 months of treatment, there were 
96 patients return normal, with 76.1% efficiency. After 6 
months of treatment, there were 5 cases of amenorrhea; 
however, during 12 months of follow-up, amenorrhea in-
creased to 9 cases (14.3%). The study showed that the drug 
having rapid hemostasis effect, with high therapeutic effect 
and cause recovery of menstruation in good condition, es-
pecially obvious in short-term effect. On the observation 
of adverse reactions in the patients of levonorgestrel treat-
ment, there was 1 case of headache (0.79%), 2 cases nausea 
(1.59%), 12 cases of slight headache (9.52%), and 20 cases 
of mild nausea (15.83%). Therefore, it is shown that the ad-
ministration of levonorgestrel cause adverse reactions such 
as headache and nausea in patients, but the adverse reac-
tion was not obvious, and the adverse reactions affecting 
small population of patients, and does not affect the whole 
treatment period [7].
As the conclusion, levonorgestrel treatment for peri-
menopausal dysfunctional uterine bleeding can effectively 
reduce the amount of menstruation discharge, increase 
hemoglobin levels, and it is economic, simple, less adverse 
reaction, with significantly short-term efficacy.
Conflicts of interest
These authors have no conflicts of interest to declare.
Authors’ contributions
These authors contributed equally to this work.
References
Kong BH. 1. not italic. normal italic 2005:384—390.
Wang JL, Zou GY. Levonorgestrel releasing intrauterine 2. 
system on functional disorders of uterine bleeding pre-
liminary observation on therapeutic effect. Beijing Medi-
cal. 2009;31(6):353—355.
Chen H, Peng LQ. Levonorgestrel intrauterine release 3. 
system in the treatment of peri menopausal dysfunction-
al uterine bleeding clinical observation. China Medical 
Guidelines. 2011;(12):7—16.
Xu XW, Yan LZ, Sun J, et al. Levonorgestrel releasing in-4. 
trauterine system in treatment of obstinate dysfunction 
uterine bleeding clinical curative effect observation. 
Journal of Medical Research. 2012;41(4):92—95.
Zhou Q. Levonorgestrel tablets in the treatment of func-5. 
tional disorders uterine bleeding clinical analysis. Chi-
nese and Foreign Medical Research. 2013;11(4):132—133.
Li N, Zhu HM. Levonorgestrel on 36 cases of observation 6. 
of the curative effect of dysfunctional uterine bleed-
ing. International Journal of Pharmaceutical Medicine. 
2012;18(6):789—792.
Qiao F, Jin L, Ai L, Zhang JS, et al. Norethindrone in the 7. 
treatment of anovulatory functional disorders of uterine 
hemorrhage curative effect analysis. China Obstetrics 
and Gynecology Journal of clinical. 2010;11(4):57—61.
Xinhui Mi and Caixia Qin
